HB0573 • 2026

Discounted Drug Pricing Study

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor: Chaney
Last action: 2026-03-13
Official status: House - Died in Health Care Facilities & Systems Subcommittee
Effective date: 2026-07-01

Plain English Breakdown

The candidate explanation incorrectly states that the bill passed both chambers and reached final enrollment. The official source indicates it died in committee.

Discounted Drug Pricing Study

This bill requires the Agency for Health Care Administration to study how drug manufacturers can sell drugs at discounted prices under Medicaid's preferred drug list and the 340B Drug Pricing Program, and provide a report by January 31, 2027.

What This Bill Does

Requires the Agency for Health Care Administration (AHCA) to conduct or contract for a detailed fiscal impact study on discounted drug pricing under the 340B Drug Pricing Program.
The study will look into how drug manufacturers can sell drugs at lower prices if they are on Medicaid's preferred drug list and covered by the 340B program.
Specifies that AHCA must provide the results of this study to the Governor, Senate President, and House Speaker by January 31, 2027.

Who It Names or Affects

The Agency for Health Care Administration (AHCA) will conduct or contract for the study.
Drug manufacturers and Medicaid pharmacies may be impacted by the findings of the study.

Terms To Know

340B Drug Pricing Program: A federal program that requires drug companies to provide outpatient drugs at a discounted price to certain health care organizations, including those serving Medicaid patients.
Medicaid preferred drug list: A list of medications recommended by the state for use in Medicaid programs due to their effectiveness and cost-effectiveness.

Limits and Unknowns

The bill does not specify how AHCA will conduct or contract for the study.
It is unclear what specific recommendations or changes may come from the results of this study.

Bill History

2026-03-13 House
• Died in Health Care Facilities & Systems Subcommittee
2026-01-13 House
• 1st Reading (Original Filed Version)
2025-12-12 House
• Referred to Health Care Facilities & Systems Subcommittee • Referred to Health Care Budget Subcommittee • Referred to Health & Human Services Committee • Now in Health Care Facilities & Systems Subcommittee
2025-12-01 House
• Filed

Official Summary Text

Discounted Drug Pricing Study; Requires AHCA to conduct or contract for specified study to determine specified information; provides requirements for such study; requires agency to provide results to Governor & Legislature by certain date.

Current Bill Text

Read the full stored bill text

HB 573 2026

CODING: Words stricken are deletions; words underlined are additions.
hb573-00
Page 1 of 3
F L O R I D A H O U S E O F R E P R E S E N T A T I V E S

A bill to be entitled 1
An act relating to discounted drug pricing study; 2
requiring the Agency for Health Care Administration to 3
conduct or contract for a specified study; providing 4
requirements for such study; requiring the agency to 5
provide the results to the Governor and the 6
Legislature by a specified date; providing an 7
effective date. 8
9
Be It Enacted by the Legislature of the State of Florida: 10
11
Section 1. (1) The Agency for Health Care Administration 12
shall conduct or contract for a detailed fiscal impact study to 13
determine the feasibility of implementing the following 14
provisions relating to discounted drug prices under the 340B 15
Drug Pricing Program: 16
(a)1. Requiring drug manufacturers to sell a drug to 17
Medicaid pharmacies at not more than the 340B Drug Pricing 18
Program discounted price if the drug is: 19
a. On the Medicaid preferred drug list as described in s. 20
409.912(5), Florida Statutes. 21
b. A covered drug under the 340B Drug Pricing Program. 22
2. Authorizing drug manufacturers to deliver drugs sold in 23
accordance with subparagraph 1. to the purchasing Medicaid 24
pharmacy by any method used by the drug manufacturer. 25

HB 573 2026

CODING: Words stricken are deletions; words underlined are additions.
hb573-00
Page 2 of 3
F L O R I D A H O U S E O F R E P R E S E N T A T I V E S

3. If a drug manufacturer sells a drug in accordance with 26
subparagraph 1. to a Medicaid pharmacy at the 340B Drug Pricing 27
Program discounted price and such discounted price is higher 28
than the state Medicaid negotiated price, requiring the drug 29
manufacturer to pay a rebate to the state equal to the 30
difference between the discounted price and the state Medicaid 31
negotiated price. 32
(b) Requiring pharmacy benefits managers participating in 33
the Medicaid program to pay a Medicaid pharmacy the 340B Drug 34
Pricing Program discounted price plus the professional 35
dispensing fee as determined under rule 59G-4.251, Florida 36
Administrative Code, as amended, for any drug that is on the 37
Medicaid preferred drug list as described in s. 409.912(5), 38
Florida Statutes, and that is a covered drug under the 340B Drug 39
Pricing Program. 40
(c)1. Requiring drug wholesalers and distributors to sell 41
a drug to a Medicaid pharmacy at the 340B Drug Pricing Program 42
discounted price if the drug is: 43
a. On the Medicaid preferred drug list as described in s. 44
409.912(5), Florida Statutes. 45
b. A covered drug under the 340B Drug Pricing Program. 46
2. Prohibiting drug wholesalers and distributors from 47
changing an existing pricing model or program that is in place 48
with a Medicaid pharmacy by exempting a drug described in 49
paragraph (a) from the pricing model or program or by 50

HB 573 2026

CODING: Words stricken are deletions; words underlined are additions.
hb573-00
Page 3 of 3
F L O R I D A H O U S E O F R E P R E S E N T A T I V E S

referencing such drug in any way in the pricing model or 51
program. 52
(d) Requiring Medicaid pharmacies to provide a covered 53
drug under the 340B Drug Pricing Program at the discounted price 54
only to Medicaid recipients. 55
(2) The agency shall submit the results of the study to 56
the Governor, the President of the Senate, and the Speaker of 57
the House of Representatives, by January 31, 2027. 58
Section 2. This act shall take effect July 1, 2026. 59